Against the backdrop of global trade policy uncertainties, even the threat of high tariffs may not be able to stop the upward momentum of certain high-quality stocks. Taking pharmaceutical giant Eli Lilly (LLY) as an example, it is skillfully navigating risks and strengthening its competitiveness through proactive strategic initiatives.
Facing potential tariff pressures that threaten the profits of many companies manufacturing products overseas, Eli Lilly has chosen to expand its domestic production base to counter this risk. The company announced on September 16 its plan to invest $5 billion in building a new pharmaceutical manufacturing facility in Virginia. This is not an isolated project but part of a larger investment plan. As early as February this year, Lilly announced it would invest a total of $27 billion into four new manufacturing sites, bringing its total capital expenditures since 2020 to over $50 billion. The Virginia facility is the first of these four planned sites and will be dedicated to producing Antibody-Drug Conjugates (ADCs), an innovative class of drugs primarily used for treating cancer, with potential applications in autoimmune diseases.
The deeper strategic intent behind this investment is to circumvent tariff risks. Once all four facilities are completed, Eli Lilly will be able to fully manufacture drugs supplied to the U.S. market domestically within the United States. This means that, regardless of how future trade policies evolve, Lilly will become a leading pharmaceutical company largely insulated from tariff impacts, thereby stabilizing its profit levels.
While strengthening internal production capacity, Eli Lilly is also actively expanding its technological boundaries through external acquisitions. The company recently announced its plan to acquire gene therapy company Adverum Biotechnologies (ADVM). According to the agreement, Lilly will initiate a tender offer to acquire Adverum at $3.56 per share, accompanied by a Contingent Value Right (CVR). If specific milestones are met, up to an additional $8.91 per share could be paid, bringing the total potential value per share to $12.47.
The core objective of this acquisition is to obtain Adverum’s lead gene therapy candidate, Ixo-vec (ixoberogene soroparvovec or Ixo-vec), an intravitreal gene therapy for wet age-related macular degeneration. Adverum focuses on developing single-administration gene therapies aimed at achieving functional cures that could restore vision and prevent blindness. Lilly stated that this merger will combine its own genetic medicines research capabilities with Adverum’s expertise in ophthalmic gene therapies, helping to expand the company’s potential in alleviating the burden of age-related diseases. The transaction is expected to be completed in the fourth quarter of 2025.
In summary, Eli Lilly demonstrates strong strategic execution. On one hand, its revenue and profit growth are exceptionally robust, with a product pipeline driven by blockbuster drugs expected to continue driving revenue growth over the next five years. On the other hand, through massive domestic investments, the company is proactively eliminating an external risk that could pressure its long-term profits. Simultaneously, the acquisition of Adverum shows its determination to pioneer in cutting-edge therapeutic areas. These moves collectively prove that Eli Lilly remains one of the most noteworthy high-quality investment targets among pharmaceutical stocks.
